
Save Billions or Stick With Humira? Drug Brokers Steer Americans to the Costly Choice
Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.